Shorter laser exposure just as effective as the conventional approach

Article

Shortening of retinal laser exposure time is just as effective as conventional, longer laser exposure in patients undergoing laser photocoagulation, but is significantly less painful, according to a study published in the January issue of Eye.

Shortening of retinal laser exposure time is just as effective as conventional, longer laser exposure in patients undergoing laser photocoagulation, but is significantly less painful, according to a study published in the January issue of Eye.

Jonathan M. Gibson, MD, and colleagues at Birmingham Heartlands and Solihull NHS Trust, UK compared short exposure, high-energy laser settings with conventional settings, using a 532 nm, frequency doubled, Neodymium-Yag laser and assessed the patients in terms of pain experienced and effectiveness of treatment.

Twenty patients with proliferative retinopathy having panretinal photocoagulation (PRP) for the first time underwent random allocation to treatment of the superior and inferior hemi-retina. Treatment A used 'conventional' parameters: exposure time 0.1 s, power sufficient to produce visible grey-white burns, and a spot size of 300 µm. The other hemi-retina was treated with treatment B using exposure 0.02 s, 300 µm spot size and sufficient power to have similar endpoint. All patients underwent fundus photography and were followed up for 6 to 45 months.

Patients were asked to evaluate severity of pain on a visual analogue scale (0=no pain, 10=most severe pain), and pain scores were found to be significantly higher in the conventional group (treatment A) compared with the short exposure group (treatment B) — 5.1 versus 1.4, respectively. Further treatments, if required, were performed with treatment B parameters and long-term follow-up showed no evidence of under-treatment.

The researchers concluded that shortening exposure time of retinal laser is significantly less painful but equally effective as conventional parameters.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.